K. Kerrigan

发表

Mutation based approaches to the treatment of anaplastic thyroid cancer

Hilary C. McCrary, J. Hunt, D. Abraham, 2022, Clinical endocrinology.

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer

K. Kerrigan, S. Puri, 2022, Current Oncology Reports.

Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit.

G. Otterson, A. Shoben, K. Kerrigan, 2016, Clinical lung cancer.

Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report

K. Kerrigan, Shiven B. Patel, Cassia R Griswold, 2019, Case Reports in Oncology.

Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group.

K. Ramchandran, P. Stetson, Travis J. Osterman, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma.

A. Rook, E. V. Van Scott, E. Vonderheid, 1998, Journal of Investigative Dermatology.

Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis

Margaret A. Johns, Melissa Gilbert-Ross, A. Marcus, 2023, bioRxiv.

Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status.

Xue-chen Wang, B. Haaland, W. Akerley, 2021, Clinical lung cancer.

A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern

B. Haaland, W. Akerley, J. Chipman, 2022, JTO clinical and research reports.

Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation

S. Lloyd, Y. Hitchcock, C. Rock, 2022, Head & neck.

Analysis of Clinical, Histopathologic and Immunopathologic Parameters in Erythrodermic Variants of Cutaneous T-Cell Lymphoma with Implications for Staging

P. Nowell, E. Pequignot, S. Lessin, 1994 .

Prognostic Significance of Patient-Reported Outcomes in Cancer.

D. Ose, N. Meropol, B. Haaland, 2020, JCO oncology practice.

Lung Cancer in Li-Fraumeni Syndrome

J. Schiffman, W. Kohlmann, J. Vagher, 2021, JCO precision oncology.

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer

D. Pinato, C. Stavraka, Saman Maleki Vareki, 2021, Annals of translational medicine.

Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins

S. Lloyd, Y. Hitchcock, D. Cannon, 2021, Head & neck.

Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.

J. Sinnott, B. Haaland, W. Akerley, 2023, Cancer treatment and research communications.

Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.

B. Halmos, T. Owonikoko, H. Borghaei, 2021, Journal of Clinical Oncology.

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

H. Soares, S. Hu-Lieskovan, J. Doherty, 2023, Frontiers in immunology.

Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy

K. Kerrigan, Shiven B. Patel, Eric D. Johnson, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.